SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation
November 15, 2023 08:01 ET
|
SciSparc Ltd
Phase IIa trial outcome indicates the potential for a new way to help Alzheimer’s patients’ agitation Tel-Aviv, Nov. 15, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty,...
SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication
November 10, 2023 09:10 ET
|
SciSparc Ltd
SciSparc to conduct trial at Yale University in the USA, Tel Aviv Sourasky Medical Center in Israel and the Hannover Medical School in Germany TEL AVIV, Israel, Nov. 10, 2023 (GLOBE NEWSWIRE) --...
SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
October 31, 2023 07:38 ET
|
SciSparc Ltd
TEL AVIV, Israel, Oct. 31, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
October 24, 2023 07:20 ET
|
SciSparc Ltd
The Company's most recent patent further solidifies its position within the cannabis sector, complementing existing grants in the U.S., Europe, and other key jurisdictions TEL AVIV, Israel, Oct. ...
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
October 16, 2023 08:17 ET
|
SciSparc Ltd
Tel Aviv, Oct. 16, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the...
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
October 13, 2023 16:28 ET
|
SciSparc Ltd
TEL AVIV, ISRAEL, Oct. 13, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”), today announced the closing of its previously announced private placement with an...
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
October 11, 2023 09:15 ET
|
SciSparc Ltd
TEL AVIV, ISRAEL, Oct. 11, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”), today announced that it has entered into a securities purchase agreement with an...
SciSparc Granted European Patent for its Core Technology
October 03, 2023 07:33 ET
|
SciSparc Ltd
The receipt of the patent confirms the innovation and uniqueness of the Company's technologies and strengthens its position as a leader in the cannabis space TEL AVIV, Israel, Oct. 03, 2023 ...
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
September 29, 2023 07:45 ET
|
SciSparc Ltd
TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
September 27, 2023 07:58 ET
|
SciSparc Ltd
Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:...